Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer’s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-5960
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer’s disease ; volume:2 ; number:1 ; day:21 ; month:10 ; year:2014 ; pages:1-14 ; date:12.2014
Acta Neuropathologica Communications ; 2, Heft 1 (21.10.2014), 1-14, 12.2014
- Urheber
-
Tai, Hwan-Ching
- Beteiligte Personen und Organisationen
-
Wang, Bo Y.
Serrano–Pozo, Alberto
Frosch, Matthew P.
Spires-Jones, Tara L.
Hyman, Bradley T.
SpringerLink (Online service)
- DOI
-
10.1186/s40478-014-0146-2
- URN
-
urn:nbn:de:1111-201605067260
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tai, Hwan-Ching
- Wang, Bo Y.
- Serrano–Pozo, Alberto
- Frosch, Matthew P.
- Spires-Jones, Tara L.
- Hyman, Bradley T.
- SpringerLink (Online service)
Ähnliche Objekte (12)
The Alzheimer’s β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques
Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Alzheimer’s disease: Amyloid oligomers, therapeutic agents, their target and mode of action
Prion protein oligomers cause neuronal cytoskeletal damage in rapidly progressive Alzheimer’s disease
Aβ oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer’s disease
Damaged mitochondria coincide with presynaptic vesicle loss and abnormalities in alzheimer’s disease brain
The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
Advancement of the detection of individual Alzheimer’s amyloid-β oligomers in biological samples
A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer’s Disease
Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease
The Alzheimer’s β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques
Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Alzheimer’s disease: Amyloid oligomers, therapeutic agents, their target and mode of action
Prion protein oligomers cause neuronal cytoskeletal damage in rapidly progressive Alzheimer’s disease
Aβ oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer’s disease
Damaged mitochondria coincide with presynaptic vesicle loss and abnormalities in alzheimer’s disease brain
The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
Advancement of the detection of individual Alzheimer’s amyloid-β oligomers in biological samples
A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer’s Disease
Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease
The Alzheimer’s β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques
Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Alzheimer’s disease: Amyloid oligomers, therapeutic agents, their target and mode of action
Prion protein oligomers cause neuronal cytoskeletal damage in rapidly progressive Alzheimer’s disease
Aβ oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer’s disease
Damaged mitochondria coincide with presynaptic vesicle loss and abnormalities in alzheimer’s disease brain
The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
Advancement of the detection of individual Alzheimer’s amyloid-β oligomers in biological samples
A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer’s Disease